Lantern Pharma (NASDAQ:LTRN) issued its quarterly earnings results on Sunday. The company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.03, MarketWatch Earnings reports.
NASDAQ LTRN traded down $0.32 during trading hours on Tuesday, hitting $15.66. 57,442 shares of the company were exchanged, compared to its average volume of 195,705. The company has a 50 day moving average of $17.79 and a two-hundred day moving average of $17.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 27.58 and a quick ratio of 27.58. Lantern Pharma has a 52-week low of $10.40 and a 52-week high of $24.84.
Lantern Pharma Company Profile
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer.
Recommended Story: What does the Dogs of the Dow mean?